公开(公告)号：US20230062491A1

公开(公告)日：2023-03-02

申请号：US17667288

申请日：2022-02-08

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Robert Zahler ,  Stephane Ciblat ,  Dana K. Winter ,  Anzhelika Kabro ,  Stephanie Roy ,  Darby Schmidt ,  Claudio Chuaqui ,  Goran Malojcic ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund ,  William Sinko ,  Kevin Sprott

IPC: C07F9/6558 ,  C07D417/14 ,  C07D471/08 ,  C07D413/14 ,  C07D401/14 ,  C07D471/04

Abstract: The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

公开(公告)号：US20240360165A1

公开(公告)日：2024-10-31

申请号：US18635402

申请日：2024-04-15

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. MARINEAU ,  Robert Zahler ,  Stephane Ciblat ,  Dana K. Winter ,  Anzhelika Kabro ,  Stephanie Roy ,  Darby Schmidt ,  Claudio Chuaqui ,  Goran Malojcic ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund ,  William Sinko ,  Kevin Sprott

IPC: C07F9/6558 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08

CPC classification number: C07F9/65583 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08

Abstract: The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

公开(公告)号：US20220305014A1

公开(公告)日：2022-09-29

申请号：US17687259

申请日：2022-03-04

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Claudio Edmundo Chuaqui ,  Stephane Ciblat ,  Anzhelika Kabro ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund

IPC: A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

公开(公告)号：US11918592B2

公开(公告)日：2024-03-05

申请号：US16962809

申请日：2019-01-16

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Claudio Edmundo Chuaqui ,  Stephane Ciblat ,  Anzhelika Kabro ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund ,  Michael Bradley

IPC: C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  A61P35/00 ,  A61K31/675 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/08 ,  C07F9/6558

CPC classification number: A61K31/675 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/08 ,  C07F9/65583

Abstract: The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

公开(公告)号：US20210379065A1

公开(公告)日：2021-12-09

申请号：US16962808

申请日：2019-01-16

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Claudio Edmundo Chuaqui ,  Stephane Ciblat ,  Anzhelika Kabro ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund

IPC: A61K31/506 ,  A61K45/06 ,  C07D413/14 ,  C07D417/14 ,  C07D401/14 ,  C07D471/04

Abstract: The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

公开(公告)号：US11311542B2

公开(公告)日：2022-04-26

申请号：US16962808

申请日：2019-01-16

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Claudio Edmundo Chuaqui ,  Stephane Ciblat ,  Anzhelika Kabro ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund

IPC: A61K45/06 ,  A61K31/506 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

公开(公告)号：US20220000890A1

公开(公告)日：2022-01-06

申请号：US16962809

申请日：2019-01-16

Applicant: Syros Pharmaceuticals, Inc.

Inventor： Jason J. Marineau ,  Claudio Edmundo Chuaqui ,  Stephane Ciblat ,  Anzhelika Kabro ,  Henri Piras ,  Kenneth Matthew Whitmore ,  Kate-Lyn Lund ,  Michael Bradley

IPC: A61K31/675 ,  A61K45/06 ,  C07D403/04 ,  C07D413/14 ,  C07D403/14 ,  C07D487/08 ,  C07D471/04 ,  C07F9/6558 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00

Abstract: The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).